منابع مشابه
Extrapyramidal side-effects of antipsychotics in a randomised trial.
BACKGROUND There are claims that second-generation antipsychotics produce fewer extrapyramidal side-effects (EPS) compared with first-generation drugs. AIMS To compare the incidence of treatment-emergent EPS between second-generation antipsychotics and perphenazine in people with schizophrenia. METHOD Incidence analyses integrated data from standardised rating scales and documented use of c...
متن کاملExtrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome.
Previously, clinicians worked with antipsychotic drugs (conventional or typical) that almost invariably caused extrapyramidal symptoms (EPS) at clinically effective doses. This led to the false impression that all antipsychotics were the same, and that EPS were an unavoidable consequence of effective antipsychotic therapy. EPS adversely impact several aspects of antipsychotic efficacy and toler...
متن کاملNeuronal basis of neuroleptic-induced extrapyramidal side effects.
The article reviews presently commonly accepted concepts of neuronal basis of neuroleptic-induced extrapyramidal side effects. The data obtained both, in humans and laboratory animals, point to the blockade of a large number of the striatal dopamine D2 receptors by neuroleptics as a primary cause of these disturbances. This phenomenon leads to the appearance of parkinsonian symptoms shortly aft...
متن کاملExtrapyramidal side-effects and antipsychotics: are second-generation agents
Peluso et al report on the differential effect of first-generation antipsychotics (FGAs) v. second-generation antipsychotics (SGAs) in ameliorating or exacerbating extrapyramidal side-effects (EPS) in a secondary analysis of the CUtLASS-1 trial data. They report their findings as ‘essentially null’ and mention that there is weak evidence for clinically significant differences in emergent or rel...
متن کاملExtrapyramidal side-effects and antipsychotics: are second-generation agents
Peluso et al report on the differential effect of first-generation antipsychotics (FGAs) v. second-generation antipsychotics (SGAs) in ameliorating or exacerbating extrapyramidal side-effects (EPS) in a secondary analysis of the CUtLASS-1 trial data. They report their findings as ‘essentially null’ and mention that there is weak evidence for clinically significant differences in emergent or rel...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: British Journal of Psychiatry
سال: 1989
ISSN: 0007-1250,1472-1465
DOI: 10.1192/bjp.155.2.269a